α-Galactosylceramide

SKU: orb1707685

Description

α-Galactosylceramide (KRN7000) is a potent synthetic glycolipid agonist of NKT cells, binding CD1d to form a complex recognized by the NKT cell receptor. It is widely used in immunology and oncology research to study NKT cell activation, cytokine responses, and antitumor immunity in both in vitro and in vivo experimental models.

Research Area

Immunology & Inflammation

Key Properties

• CAS Number: 158021-47-7
• MW: 858.32
• Purity: 98.00% (May vary between batches)
• Formula: C₅₀H₉₉NO₉
• SMILES: CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC
• Target: Interleukin,Others
• Solubility: DMSO:1 mg/mL (1.17 mM)

Bioactivity

• In Vivo:
  α-Galactosylceramide treatment prevents spontaneous, oncogenic, or oncogene-induced primary tumor formation in mice. Consistent with a major role of IFN-γ in NKT cell-mediated tumor responses, the C-glycoside analog of α-Galactosylceramide, which preferentially stimulates IFN-γ production, was even more effective than α-galactose in preventing B16 melanoma metastasis. Ceramides are more effective . α-Galactosylceramide showed potent antitumor activity and stimulated lymphocyte proliferation (LP) in mouse allogeneic mixed lymphocyte reaction (MLR) .
• In Vitro:
  Stimulation of activated Vα24+ NKT cell cultures with α-Galactosylceramide-pulsed monocyte-derived dendritic cells (Mo-DC) has antiproliferative activity against melanoma cells. Antiproliferative effects of Vα24+ NKT cells stimulated by α-Galactosylceramide-pulsed Mo-DCs via soluble mediators have antitumor activity against human melanoma. This effect is mainly due to the release of IFN-γ and, to a lesser extent, IL-12. Other cytokines, including IL-4 and IL-10, are released, but these cytokines have less antiproliferative effects .

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

alpha-Galactosylceramide, alpha-GalCer, a-Galactosylceramide, a-GalCer, antitumorial, CD1d, cell, immunostimulatory, inhibit, KRN 7000, KRN7000, KRN-7000, NKT, NKT cell, Inhibitor, glycolipid, α Galactosylceramide, αGalactosylceramide, α-Galactosylceramide, α-GalCer, Synthesis, TCR

Compound Identifiers

PubChem CID

2826713